Pharma Mar SA (PHM) Price & Analysis

Compare

17 Followers

PHM Stock Chart & Stats

€78.00

€0.65(0.83%)

At close: Jan 09 4:00 PM EST

€78.00

€0.65(0.83%)

Day’s Range― - ―

52-Week Range€65.00 - €102.40

Previous CloseN/A

Volume4.24K

Average Volume (3M)74.16K

Market Cap

€1.38B

Enterprise Value€1.43B

Total Cash (Recent Filing)€167.22M

Total Debt (Recent Filing)€50.55M

Price to Earnings (P/E)18.1

Beta0.99

Next Earnings

Apr 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.04%

Share Statistics

EPS (TTM)3.42

Shares Outstanding18,000,000

10 Day Avg. Volume71,270

30 Day Avg. Volume74,161

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)5.12

Price to Sales (P/S)5.82

P/FCF Ratio29.46

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€120.00

Price Target Upside53.85% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)2.4

Revenue Forecast (FY)€218.57M

Bulls Say, Bears Say

Bulls Say

Revenue And Profit ReboundA durable recovery in top-line and margins indicates the business can convert regulatory and commercial wins into recurring revenue streams. Strong 2025 growth reflects diversified revenue sources (sales, royalties, licensing), improving predictability versus prior down cycles and supporting continued reinvestment.

Cash Generation And Balance SheetMaterial positive operating cash flow and sizeable cash reserves provide durable funding for launches, R&D, and potential bolt-on deals without heavy new leverage. This strengthens financial optionality and lowers refinancing pressure while enabling measured capital allocation over the next several quarters.

Regulatory And Pipeline CatalystsClear near‑term regulatory milestones and active pivotal trials (LAGOON, SaLuDo, PM54/PM534) create structural upside to the commercial base. Successful approvals and trial readouts would expand addressable markets and lengthen revenue runways beyond current products.

Bears Say

Earnings And Cash-Flow VolatilityHistorically large swings in revenue and FCF reduce the predictability of earnings and capital planning. This structural variability raises execution risk for launches, complicates long-term budgeting, and can require higher cash buffers or contingent funding during negative cycles.

Dependence On Partners For CommercializationHeavy partner reliance limits PharmaMar's control over market rollout, disclosures and timing. This structural dependency can mute upside, create asymmetric information, and expose revenue to partner performance, contract terms, and inventory/distribution decisions outside company control.

Generic Competition Risk For YondelisEstablished generics in Europe and uncertain U.S. patent outcomes pose a durable headwind to royalty and sales streams from Yondelis. This structural erosion risk can compress long‑term revenue and margins, increasing reliance on new approvals and pipeline commercialization to replace lost cash flows.

Pharma Mar SA News

Pharma Mar Continues Share Buyback With February Purchases on Madrid Exchange

Pharma Mar SA ( ($ES:PHM) ) just unveiled an update. Pharma Mar SA has continued its previously announced...

2d ago

PHMMF Upcoming Earnings Report: What to Expect?

Pharma Mar SA (PHMMF) is scheduled to report 4th quarter earnings on 03/02/2026. Regarding Q4 estimates, Wall Street...

5d ago

Pharma Mar Details January Transactions in Ongoing Share Buyback Programme

An announcement from Pharma Mar SA ( ($ES:PHM) ) is now available. Pharma Mar has continued its previously...

30d ago

Pharma Mar SA Reports Revenue Growth and Key Approvals

Pharma Mar SA ( ($PHMMF) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

Pharma Mar SA Reports Strong H1 2025 Performance

Pharma Mar SA ( ($PHMMF) ) has released its Q2 earnings. Here is a breakdown of the information...

7M ago

Pharma Mar Concludes Share Buy-back Program Early

Pharma Mar SA ( ($ES:PHM) ) has provided an announcement. Pharma Mar SA has completed its share buy-back...

9M ago

Pharma Mar SA Announces Dividend Payment for 2025

The latest announcement is out from Pharma Mar SA ( ($ES:PHM) ). Pharma Mar SA announced the payment...

9M ago

Pharma Mar S.A. Shareholders Approve Board Proposals

Pharma Mar SA ( ($ES:PHM) ) has shared an announcement. Pharma Mar S.A. held its Ordinary General Meeting...

9M ago

Pharma Mar’s Strategic Shareholder Meeting

Pharma Mar SA ( ($ES:PHM) ) has provided an update. Pharma Mar SA announced that its Chairman and...

9M ago

Pharma Mar’s Zepzelca® Shows Promising Results in Lung Cancer Treatment

Pharma Mar SA ( ($ES:PHM) ) has shared an update. Pharma Mar SA announced positive results from the...

9M ago

Pharma Mar downgraded to Neutral from Outperform at Oddo BHF

Oddo BHF analyst Juan Ros Padilla downgraded Pharma Mar to Neutral from Outperform with a EUR 48 price...

1y ago

Pharma Mar initiated with a Buy at Chardan

Chardan initiated coverage of Pharma Mar with a Buy rating and EUR 60 price target. The analyst cites...

2y ago

PHM FAQ

What was Pharma Mar SA’s price range in the past 12 months?

Pharma Mar SA lowest stock price was €65.00 and its highest was €102.40 in the past 12 months.

What is Pharma Mar SA’s market cap?

Pharma Mar SA’s market cap is €1.38B.

When is Pharma Mar SA’s upcoming earnings report date?

Pharma Mar SA’s upcoming earnings report date is Apr 23, 2026 which is in 49 days.

How were Pharma Mar SA’s earnings last quarter?

Pharma Mar SA released its earnings results on Mar 02, 2026. The company reported €3.423 earnings per share for the quarter, beating the consensus estimate of €3.335 by €0.088.

Is Pharma Mar SA overvalued?

According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharma Mar SA pay dividends?

Pharma Mar SA pays a Annually dividend of €0.8 which represents an annual dividend yield of 1.04%. See more information on Pharma Mar SA dividends here

What is Pharma Mar SA’s EPS estimate?

Pharma Mar SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharma Mar SA have?

Pharma Mar SA has 18,000,000 shares outstanding.

What happened to Pharma Mar SA’s price movement after its last earnings report?

Pharma Mar SA reported an EPS of €3.423 in its last earnings report, beating expectations of €3.335. Following the earnings report the stock price went up 4.922%.

Which hedge fund is a major shareholder of Pharma Mar SA?

Currently, no hedge funds are holding shares in ES:PHM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharma Mar SA Stock Smart Score

Neutral

Fundamentals

Return on Equity

17.22%

Trailing 12-Months

Asset Growth

20.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Pharma Mar SA (PHM) Earnings & Revenues

Historic Earnings Reports

PHM Company Deck

PHM Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all ES:PHM earnings summaries

PHM Stock 12 Month Forecast

Average Price Target

€120.00

▲(53.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"€72","84":"€84","96":"€96","108":"€108","120":"€120"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":119.9999999061864,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119.9994155074,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119.9999999061864,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€120.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[72,84,96,108,120],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.2,86.95384614662973,89.70769229325946,92.46153843988917,95.2153845865189,97.96923073314862,100.72307687977835,103.47692302640806,106.23076917303779,108.98461531966751,111.73846146629724,114.49230761292696,117.24615375955668,{"y":119.9999999061864,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.2,86.95380119287692,89.70760238575384,92.46140357863078,95.2152047715077,97.96900596438462,100.72280715726154,103.47660835013846,106.23040954301538,108.9842107358923,111.73801192876923,114.49181312164616,117.24561431452308,{"y":119.9994155074,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.2,86.95384614662973,89.70769229325946,92.46153843988917,95.2153845865189,97.96923073314862,100.72307687977835,103.47692302640806,106.23076917303779,108.98461531966751,111.73846146629724,114.49230761292696,117.24615375955668,{"y":119.9999999061864,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":94.858,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.857,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.619,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.481,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.25,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":84,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":94.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.15,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.9,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":76.6,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":84.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >